acebutolol and dasatinib

acebutolol has been researched along with dasatinib in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Bua, M; Clark, R; Gerrard, G; Goldman, J; Lucas, C; Marin, D; May, P; Milojkovic, D; Neelakantan, P; O'Brien, S; Paliompeis, C; Reid, A; Rezvani, K; Wang, L	1

Reviews

1 review(s) available for acebutolol and dasatinib

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

1 trial(s) available for acebutolol and dasatinib

Article	Year
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood, 2013, Apr-04, Volume: 121, Issue:14 Topics: Acebutolol; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Predictive Value of Tests; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome	2013

Article

Year

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.

Blood, 2013, Apr-04, Volume: 121, Issue:14

Topics: Acebutolol; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Predictive Value of Tests; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome

2013

Other Studies

1 other study(ies) available for acebutolol and dasatinib

Article	Year
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorganic & medicinal chemistry, 2009, Oct-01, Volume: 17, Issue:19 Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship	2009

Article

Year

Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.

Bioorganic & medicinal chemistry, 2009, Oct-01, Volume: 17, Issue:19

Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship

2009